CN106729610A - Purposes of the N15 polypeptides in staphylococcus aureus inhibitor is suppressed - Google Patents
Purposes of the N15 polypeptides in staphylococcus aureus inhibitor is suppressed Download PDFInfo
- Publication number
- CN106729610A CN106729610A CN201611169791.6A CN201611169791A CN106729610A CN 106729610 A CN106729610 A CN 106729610A CN 201611169791 A CN201611169791 A CN 201611169791A CN 106729610 A CN106729610 A CN 106729610A
- Authority
- CN
- China
- Prior art keywords
- polypeptides
- staphylococcus aureus
- genes
- purposes
- biological function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 23
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 23
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 21
- 239000003112 inhibitor Substances 0.000 title claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000000941 anti-staphylcoccal effect Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000008827 biological function Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 108050006400 Cyclin Proteins 0.000 abstract description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract description 2
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 2
- 208000001126 Keratosis Diseases 0.000 abstract description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 abstract description 2
- 108091023040 Transcription factor Proteins 0.000 abstract description 2
- 102000040945 Transcription factor Human genes 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 230000036566 epidermal hyperplasia Effects 0.000 abstract description 2
- 206010020718 hyperplasia Diseases 0.000 abstract description 2
- 238000010606 normalization Methods 0.000 abstract description 2
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses purposes of the N15 polypeptides in staphylococcus aureus inhibitor is prepared, N15 polypeptides are one has 15 small peptides of amino acid, it has various biological function, ability including adjusting NF κ B transcription factor binding purpose genes, influences the transcript and expression of NF κ B genes of interest product albumen matter；Blocking PCNA combination archaeal dna polymerases, so that preventing cell DNA from synthesizing suppresses cell propagation；Suppress epithelial hyperplasia, adjust epidermal hyperplasia and differentiation, make Keratoderma process normalization etc., disclosure sets forth its new biological function, with preferable practicality and industrialization prospect.
Description
Technical field
The present invention relates to biological technical field, use of the N15 polypeptides in staphylococcus aureus inhibitor is prepared is referred specifically to
On the way.
Background technology
Staphylococcus aureus pathogenicity is most strong, mainly produces hemolysin, leukocidin and plasma-coagulase etc., causes
Perhaps multi-infection, such as furuncle, carbuncle, abscess and wound infection.The characteristics of infection of staphylococcus aureus is limitation necrosis,
It is fester stiff, yellow, not smelly.Also systemic infection can be caused, health is influenceed, human life's safety is threatened.In order to suppress
With eliminate disease fungus, people are devoted to finding effective pathogenic bacteria medicine always.
The content of the invention
It is an object of the invention to provide a kind of polypeptide, the polypeptide can suppress the growth of staphylococcus aureus, have
Purposes in pathogenetic bacteria inhibitor is prepared, it is disclosed by prior art, entitled N15 polypeptides.
N15 polypeptides are one has 15 small peptides of amino acid, and its sequence is Met-Pro-tyrosine-silk ammonia
Acid-TE-Leu-Ile-phenylalanine-tyrosine-lle-Glu-methionine-day
L-aminobutanedioic acid-proline, it has a various biological function, including regulation NF- κ B transcription factor binding purpose genes ability,
Influence the transcript and expression of NF- κ B genes of interest product albumen matter；Blocking PCNA combination archaeal dna polymerases, so as to prevent cell DNA
Synthesis suppresses cell propagation；Suppress epithelial hyperplasia, adjust epidermal hyperplasia and differentiation, make Keratoderma process normalization etc..
Inventor has found to find that N15 polypeptides can produce inhibitory action to the growth of various pathogenetic bacterias under study for action.
Early-stage Study shows, adds N15 to play suppression staphylococcus aureus in staphylococcus aureus and breed
Effect.By detecting that DNA content finds in staphylococcus aureus, N15 can cause the DNA content in staphylococcus aureus
Reduce, therefore the propagation of N15 suppression staphylococcus aureuses may be by suppressor group DNA replication dna and realize.Additionally,
Experimental result also shows that N15 can suppress the growth of salmonella.
It is the aqueous solution of N15 polypeptides present invention also offers antifungal drug prepared by a kind of N15 polypeptides, concentration is more than
Equal to 500 μ g/mL.
Beneficial effects of the present invention：N15 polypeptides are a kind of clear in structure, it is easy to the polypeptide of industrialized production, and it can press down
The propagation of various pathogenetic bacterias is made, effect is good and has no toxic side effect.
Brief description of the drawings
Fig. 1 is influences of the flow cytomery N15 to L-form staphylococcus aureus content.
Specific embodiment
Make further demonstration explanation to the present invention with specific experiment example below in conjunction with the accompanying drawings, following experimental example is only to this
The explanation of invention and the invention is not limited in following experimental example.
Experimental example 1：Growths of the N15 to staphylococcus aureus is inhibited
Experimental technique：
Take staphylococcus aureus strains to be inoculated on beef-protein medium inclined-plane, activation culture at 37 DEG C, use
Oese under inoculated and cultured sterile working, 100 μ L bodies is drawn with liquid getting device from bacterium is chosen on inclined-plane to bacteria suspension is made in sterilized water
Long-pending bacterium solution after fully mixing, is injected into sterilizing plates rapidly in the small centrifuge tube of sterilizing, and N15 polypeptides are added in flat board,
Blank is made with the mixed liquor injection of the sterilized water of same volume, is placed in 37 DEG C of constant incubators and is cultivated 48 hours, observation bacterium colony life
Situation long, and to colony counting, the results are shown in Table 1.
Table 1.N15 is to the staphylococcus aureus growth histamine result table of comparisons
Result shows, is compared with control that the clump count of staphylococcus aureus substantially subtracts on the flat board of addition N15 polypeptides
Few, growths of the N15 to staphylococcus aureus has depression effect.
Experimental example 2：N15 has depression effect to the DNA replication dna of staphylococcus aureus
Experimental technique：
YEPD fluid nutrient mediums are prepared, cultivate staphylococcus aureus, and add N15 to YEPD fluid nutrient mediums, together
When set and be not added with the staphylococcus aureus of N15 polypeptides as control (control), add N15 polypeptides (the μ g/ of final concentration 500
ML), 2 hours separately sampled 2mL staphylococcus aureuses thalline are being processed, is adding Sytox-Green dyestuffs to golden yellow grape
After pneumoniae cells DNA dyeing, the DNA relative amounts for carrying out staphylococcus aureus using flow cytometer are measured, as a result
See Fig. 1.
As shown in experimental result, abscissa represents the content of DNA in single aureus cell, and ordinate is represented
Number of yeast cells.Processed in 2 hours in N15, the intracellular DNA content of N15 treatment compares no conspicuousness with compared with control cells
Difference, and increase over time, after N15 is processed 15 hours, N15 processes intracellular DNA content and compared with control cells phase
Than significantly reducing.The result shows that N15 can cause the reduction of aureus cell DNA content.
Claims (2)
- Purposes of the 1.N15 polypeptides in staphylococcus aureus inhibitor is prepared.
- 2. the anti-Staphylococcus aureus medicine that prepared by a kind of N15 polypeptides, it is characterised in that：The anti-Staphylococcus aureus medicine Thing is the aqueous solution of N15 polypeptides, and concentration is more than or equal to 500 μ g/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611169791.6A CN106729610B (en) | 2016-12-16 | 2016-12-16 | Application of N15 polypeptide in inhibiting staphylococcus aureus inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611169791.6A CN106729610B (en) | 2016-12-16 | 2016-12-16 | Application of N15 polypeptide in inhibiting staphylococcus aureus inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106729610A true CN106729610A (en) | 2017-05-31 |
| CN106729610B CN106729610B (en) | 2021-01-29 |
Family
ID=58892283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611169791.6A Active CN106729610B (en) | 2016-12-16 | 2016-12-16 | Application of N15 polypeptide in inhibiting staphylococcus aureus inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729610B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368214A (en) * | 2020-07-26 | 2021-09-10 | 武汉益承生物科技有限公司 | Application of polypeptide in preparing medicine for treating wound |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565621A (en) * | 2003-07-07 | 2005-01-19 | 夏献民 | Obtainment of cell growth inhibiting polypeptide and its usage |
| CN1766110A (en) * | 2005-09-13 | 2006-05-03 | 四川大学华西医院 | Miniaturized Staphylococcus aureus polypeptide of against drug resistance and application thereof and preparation method |
| CN102321158A (en) * | 2011-08-23 | 2012-01-18 | 常州德健生物科技有限公司 | Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| CN104043102A (en) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | Use of polypeptide in preparation of drug for treating nuclear factor-kB abnormal activation diseases |
-
2016
- 2016-12-16 CN CN201611169791.6A patent/CN106729610B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565621A (en) * | 2003-07-07 | 2005-01-19 | 夏献民 | Obtainment of cell growth inhibiting polypeptide and its usage |
| CN1766110A (en) * | 2005-09-13 | 2006-05-03 | 四川大学华西医院 | Miniaturized Staphylococcus aureus polypeptide of against drug resistance and application thereof and preparation method |
| CN102321158A (en) * | 2011-08-23 | 2012-01-18 | 常州德健生物科技有限公司 | Polypeptide for preventing cell DNA synthesis and inhibiting cell proliferation and application |
| CN104043102A (en) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | Use of polypeptide in preparation of drug for treating nuclear factor-kB abnormal activation diseases |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368214A (en) * | 2020-07-26 | 2021-09-10 | 武汉益承生物科技有限公司 | Application of polypeptide in preparing medicine for treating wound |
| WO2022022475A1 (en) * | 2020-07-26 | 2022-02-03 | 武汉益承生物科技有限公司 | Use of polypeptide in preparation of wound treatment drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106729610B (en) | 2021-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113142245B (en) | Synergistic prevention and treatment of common thrips by Beauveria bassiana SB038 and spinetoram | |
| CN113142244A (en) | Synergistic prevention and treatment of common thrips by Beauveria bassiana SB063 and spinetoram | |
| CN113040390B (en) | Probiotic salt-tolerant lactobacillus johnsonii and application thereof in preventing and treating pathogenic bacteria in livestock and poultry aquiculture | |
| CN105861333A (en) | Eurotium cristatum LS1 strain | |
| CN101182469A (en) | Aspergillus niger strain having highly-resistant activity to carbendazol and uses thereof | |
| CN105296386B (en) | The interior raw bacillus amyloliquefaciens of one plant height production antagonism tobacco bacterial wilt active material | |
| CN114276958A (en) | Preparation method and application of triple probiotic fermented compound with anti-inflammatory effect | |
| CN104450580A (en) | Preparation method of actinomycin D and application thereof | |
| CN107760758A (en) | Macleaya cordata extracts are to Antimicrobial effect and the measure of minimal inhibitory concentration | |
| CN107629985B (en) | Plant endophytic bacterium with antagonistic effect on plant pathogenic fungi | |
| CN106729610A (en) | Purposes of the N15 polypeptides in staphylococcus aureus inhibitor is suppressed | |
| CN108715817B (en) | Streptomyces albidoflavus strain and application thereof | |
| CN101124317A (en) | Method of modifying the viability of a lyophilized microorganism by treating the growth medium thereof with gases | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN107841474A (en) | A kind of pond life Delftiatsuruhatensis and its application in rice green smut preventing and treating | |
| CN104304251B (en) | A kind of azoles is for the preparation of the purposes of disinfectant use in agriculture | |
| CN104120084B (en) | A kind of yellowish green green muscardine fungus MFYY090714 and its application | |
| CN108294049B (en) | A kind of Paenibacillus polymyxa culture solution combination drug and preparation method thereof for treating Citrus Huanglongbing pathogen | |
| CN106729609B (en) | Application of N15 polypeptide in preparation of bacterial inhibitor | |
| CN115491327B (en) | Paenibacillus polymyxa for inhibiting malassezia and application thereof | |
| CN103947684A (en) | Application of mixed formula preparation in prevention and treatment of brown planthopper | |
| CN108812693A (en) | Application of the graphene oxide in terms of improving plant phytophthora germ Antagonistic Fungi preventive effect | |
| Dinesh et al. | Study of antifungal activity of boric acid on vaginal pathogens | |
| CN109925503A (en) | A kind of traditional Chinese medicine reversing drug resistance of Staphylococcus aureus | |
| CN109892342B (en) | Pink trichotheca and veratrine combined biological control agent and application thereof in control of corn northern leaf blight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240509 Address after: 430000, Building C4-1, Biotech Innovation Park, No. 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Yi Bio Technology Co.,Ltd. Country or region after: China Address before: 430068 No. 28 Nanli Road, Hongshan District, Wuhan City, Hubei Province Patentee before: HUBEI University OF TECHNOLOGY Country or region before: China |